GO:1905580 positive regulation of ERBB3 signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1905580 describes any process that activates or increases the frequency, rate or extent of ERBB3 (HER3) signaling.
• ERBB3 is a pseudokinase receptor that depends on heterodimerization, most notably with ERBB2, to drive downstream PI3K/AKT and MAPK signaling.
• Positive regulation of ERBB3 signaling is frequently hijacked in cancer, where ERBB3 overexpression or ligand availability promotes proliferation, survival, and therapy resistance.
• Non-coding RNAs and feedback loops, such as circSETD3/miR-4667-5p and miR-17-5p/miR-20a-5p, can modulate ERBB3 signaling in colorectal and liver cancers.
• Subtype-specific ERBB3 enrichment in basal-like breast cancer is controlled by the GATA2/GATA3-FOXA1 transcriptional axis.
• CRISPR knockout, point mutation, knock-in, and overexpression models are essential to dissect causal roles of ERBB3 pathway components.
Description
The Gene Ontology term GO:1905580, positive regulation of ERBB3 signaling pathway, refers to any process that activates or increases the frequency, rate or extent of signaling through the ERBB3 receptor tyrosine kinase. ERBB3 (also known as HER3) is a member of the EGFR/ERBB family and is unusual because it lacks intrinsic kinase activity; instead, it relies on heterodimerization with other ERBB receptors, particularly ERBB2, to propagate signals. This term captures the diverse molecular events that enhance ERBB3 pathway output, including ligand binding, receptor dimerization, and downstream adaptor recruitment. Researchers study this process because dysregulated ERBB3 signaling is a recurrent feature of many cancers and contributes to resistance to targeted therapies. Understanding the positive regulation of ERBB3 signaling is therefore critical for identifying biomarkers and developing combination treatments. The pathway is also relevant in cardiac biology, where neuregulin-1/ERBB2-ERBB3 signaling supports cardiomyocyte survival and function. This article synthesizes current knowledge from authoritative GO annotations and peer-reviewed literature to provide a research-grade overview of GO:1905580, its mechanisms, key genes, disease links, and experimental models.
positive regulation of ERBB3 signaling pathway At A Glance
| GO ID | GO:1905580 |
|---|---|
| GO term | positive regulation of ERBB3 signaling pathway |
| Ontology | biological_process |
| Synonym | activation of ERBB3 signaling pathway; upregulation of HER3 signaling pathway; positive regulation of receptor tyrosine-protein kinase erbB-3 signaling pathway |
| Major function | Enhances signal transduction through the ERBB3 (HER3) receptor, typically via heterodimerization with ERBB2 and downstream PI3K/AKT and MAPK activation. |
| Related receptor | ERBB3 (HER3), a pseudokinase that requires a partner receptor for signaling. |
| Key ligands | Neuregulins (NRG1, NRG2), which bind ERBB3 and promote heterodimerization. |
| Downstream pathways | PI3K/AKT, MAPK/ERK, and NF-κB signaling. |
| Disease relevance | Implicated in breast, colorectal, hepatocellular, and ovarian cancers, as well as cardiotoxicity. |
What Is GO:1905580?
GO:1905580 is a biological process term defined as any process that activates or increases the frequency, rate or extent of the ERBB3 signaling pathway. In other words, it encompasses all molecular events that positively regulate signal transduction initiated by the ERBB3 receptor, from ligand-induced activation to downstream effector engagement. This term is distinct from the ERBB3 signaling pathway itself (GO:0038129) because it specifically describes the regulatory inputs that enhance pathway activity.
Why Is positive regulation of ERBB3 signaling pathway Important in Cell Biology?
Positive regulation of ERBB3 signaling is critically important because ERBB3 is a central node in cellular growth and survival networks, and its hyperactivation drives tumorigenesis and therapeutic resistance. Unlike EGFR or ERBB2, ERBB3 is a pseudokinase, making it an attractive but challenging drug target; understanding its positive regulators can reveal new vulnerabilities. In the heart, neuregulin-1/ERBB2-ERBB3 signaling is essential for cardioprotection, and its unintended inhibition can cause cardiotoxicity. Thus, dissecting the mechanisms that enhance ERBB3 signaling has broad implications for oncology and cardiovascular medicine.
• ERBB3 signaling promotes cancer cell proliferation and survival in multiple malignancies.
• Positive regulation of ERBB3 contributes to resistance to EGFR- and ERBB2-targeted therapies.
• ERBB3 is a pseudokinase, so its activation depends on heterodimerization, making regulatory mechanisms key.
• Non-coding RNAs can enhance or inhibit ERBB3 signaling, offering therapeutic targets.
• Transcriptional regulators such as GATA2/GATA3 and FOXA1 control ERBB3 expression in breast cancer subtypes.
• Neuregulin-1/ERBB2-ERBB3 signaling is cardioprotective, and its modulation is relevant to onco-cardiology.
• DUSP6 inhibition can sensitize ovarian cancer cells to chemotherapy via ERK signaling, intersecting with ERBB3 networks.
• UHRF2 upregulates ErbB3/Ras/Raf signaling to promote hepatocellular carcinoma progression.
• miR-17-5p and miR-20a-5p suppress metastasis by blocking the HGF/ERBB3-NF-κB feedback loop.
• Understanding positive regulation aids in designing combination therapies that co-target ERBB3 and its partners.
What Happens During positive regulation of ERBB3 signaling pathway?
Ligand binding and receptor activation
In simple terms: A growth factor binds to ERBB3, causing it to pair with another receptor and start signaling.
Positive regulation of ERBB3 signaling often begins with the binding of neuregulin-1 (NRG1) or other ligands to the ERBB3 extracellular domain. This binding induces a conformational change that promotes heterodimerization with a partner receptor, most commonly ERBB2, which possesses active kinase activity. The heterodimer then trans-phosphorylates ERBB3 on specific tyrosine residues, creating docking sites for downstream signaling molecules. This step is a key point of positive regulation because increased ligand availability or receptor abundance enhances the signal.
Heterodimerization and transphosphorylation
In simple terms: ERBB3 needs a partner to work; when they pair up, the partner activates ERBB3 by adding phosphate tags.
ERBB3 lacks intrinsic kinase activity, so its activation strictly depends on heterodimerization with a kinase-competent ERBB family member, typically ERBB2. The formation of ERBB2-ERBB3 heterodimers is the most potent signaling unit, leading to transphosphorylation of the ERBB3 C-terminal tail. Positive regulators of this process include proteins that stabilize the heterodimer or enhance ERBB2 expression. In cancer, overexpression of ERBB2 or ERBB3 shifts the equilibrium toward active heterodimers, amplifying downstream signals.
Downstream signaling cascades
In simple terms: Once activated, ERBB3 sends signals through PI3K/AKT and MAPK pathways to promote cell growth and survival.
Phosphorylated ERBB3 recruits the p85 subunit of PI3K, leading to AKT activation, which promotes cell survival and proliferation. ERBB3 also engages the Ras/Raf/MAPK cascade, either directly or via heterodimer partners. Positive regulation of ERBB3 signaling can occur through enhanced recruitment of these adaptors or through feedback loops that sustain pathway activity. For example, circSETD3 interrupts a bidirectional positive feedback loop between ErbB3 and Akt in colorectal cancer, highlighting the interplay between ERBB3 and downstream effectors.
Transcriptional and post-transcriptional control
In simple terms: Cells can make more or less ERBB3 by controlling gene expression and RNA stability.
The abundance of ERBB3 at the cell surface is a major determinant of signaling output. Transcription factors such as GATA2, GATA3, and FOXA1 regulate ERBB3 expression in a subtype-specific manner in breast cancer. MicroRNAs, including miR-17-5p and miR-20a-5p, can directly target ERBB3 or its partners to suppress signaling. Conversely, UHRF2 upregulates ErbB3/Ras/Raf signaling in hepatocellular carcinoma, demonstrating positive regulation at the transcriptional level. These layers of control ensure that ERBB3 signaling is finely tuned.
Feedback and crosstalk with other pathways
In simple terms: Other signaling pathways can boost or dampen ERBB3 signals, creating complex feedback loops.
Positive regulation of ERBB3 signaling is not isolated; it integrates with other pathways. For instance, the HGF/ERBB3-NF-κB positive feedback loop promotes metastasis in hepatocellular carcinoma, and miR-17-5p/miR-20a-5p can block this loop. DUSP6, a phosphatase that regulates ERK, can influence ERBB3-driven ERK signaling in ovarian cancer. Such crosstalk means that targeting ERBB3 alone may be insufficient, and combination strategies are often needed.
Key Genes Involved in GO:1905580 positive regulation of ERBB3 signaling pathway
The following genes and proteins are central to the positive regulation of ERBB3 signaling, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ERBB3 | Pseudokinase receptor that initiates signaling upon heterodimerization | Core component of the pathway; target for knockout and point mutation studies |
| ERBB2 | Kinase-active partner that transphosphorylates ERBB3 | Key heterodimer partner; overexpression models mimic cancer |
| NRG1 | Ligand that binds ERBB3 and induces heterodimerization | Positive regulator; used in ligand stimulation experiments |
| PIK3R1 | p85 subunit of PI3K recruited to phosphorylated ERBB3 | Downstream effector; knockout affects AKT signaling |
| AKT1 | Serine/threonine kinase activated downstream of ERBB3 | Survival signaling; point mutations used to study activation |
| UHRF2 | Upregulates ErbB3/Ras/Raf signaling in HCC | Potential oncogene; overexpression and knockout models |
| GATA2 | Transcription factor regulating ERBB3 expression | Subtype-specific regulation in breast cancer |
| GATA3 | Transcription factor regulating ERBB3 expression | Breast cancer subtype marker; knockout alters ERBB3 levels |
| FOXA1 | Transcription factor cooperating with GATA2/3 | Regulates ERBB3 enrichment in basal-like breast cancer |
| MIR17HG | Host gene for miR-17-5p and miR-20a-5p | Non-coding RNA regulator of ERBB3 signaling |
| DUSP6 | Phosphatase that regulates ERK signaling | Modulates ERBB3-driven ERK output; inhibition sensitizes to chemo |
| NFKB1 | Transcription factor in NF-κB pathway | Part of HGF/ERBB3-NF-κB feedback loop |
| HGF | Ligand for MET that crosstalks with ERBB3 | Promotes metastasis via ERBB3-NF-κB loop |
| RAS | Small GTPase in MAPK pathway | Downstream of ERBB3; mutations affect signaling |
| RAF | Kinase in MAPK pathway | Downstream effector; targeted in ERBB3-driven cancers |
| ERK1/2 | MAP kinases downstream of ERBB3 | Readout of pathway activity; regulated by DUSP6 |
| CircSETD3 | Circular RNA that sponges miR-4667-5p | Interrupts ErbB3-Akt feedback in colorectal cancer |
| miR-4667-5p | MicroRNA targeting ERBB3/Akt feedback | Modulates cetuximab resistance |
How Is positive regulation of ERBB3 signaling pathway Regulated?
Positive regulation of ERBB3 signaling is controlled at multiple levels. Transcriptional regulation by GATA2, GATA3, and FOXA1 determines ERBB3 abundance in breast cancer subtypes. Post-transcriptional regulation by microRNAs such as miR-17-5p, miR-20a-5p, and miR-4667-5p can either suppress or enhance pathway activity. Protein-level regulation includes heterodimerization with ERBB2 and transphosphorylation. Feedback loops, such as the HGF/ERBB3-NF-κB loop, can sustain signaling, while phosphatases like DUSP6 can dampen ERK output. Additionally, UHRF2 upregulates ErbB3/Ras/Raf signaling, acting as a positive regulator in hepatocellular carcinoma. These layers ensure tight control, and their dysregulation contributes to disease.
positive regulation of ERBB3 signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ERBB3 | Breast cancer, colorectal cancer, HCC | Knockout and overexpression in cancer cell lines |
| ERBB2 | Breast cancer, cardiotoxicity | Conditional knockout in cardiomyocytes |
| UHRF2 | Hepatocellular carcinoma | Overexpression and knockout in HCC cells |
| GATA3 | Basal-like breast cancer | CRISPR knockout in breast cancer organoids |
| DUSP6 | Ovarian cancer chemoresistance | Knockout and point mutation in ovarian cancer cells |
ERBB3 signaling in cancer
Dysregulated positive regulation of ERBB3 signaling is a hallmark of many cancers. In breast cancer, ERBB3 is enriched in basal-like subtypes via the GATA2/GATA3-FOXA1 axis, promoting aggressive phenotypes. In colorectal cancer, circSETD3 interrupts the ErbB3-Akt positive feedback loop, and its loss leads to cetuximab resistance. Hepatocellular carcinoma progression is driven by UHRF2-mediated upregulation of ErbB3/Ras/Raf signaling. Ovarian cancer cells can be sensitized to chemotherapy by inhibiting DUSP6, which regulates ERK signaling downstream of ERBB3. These examples underscore the therapeutic potential of targeting positive regulators of ERBB3.
Cardioprotective roles and onco-cardiology
Neuregulin-1/ERBB2-ERBB3 signaling is essential for cardiomyocyte survival and function, and its positive regulation is cardioprotective. However, cancer therapies that inhibit ERBB2 (e.g., trastuzumab) can inadvertently block ERBB3 signaling in the heart, leading to cardiotoxicity. Understanding the balance between beneficial cardiac ERBB3 signaling and detrimental cancer ERBB3 signaling is a key challenge in onco-cardiology.
Therapeutic resistance
Positive regulation of ERBB3 signaling contributes to resistance to EGFR- and ERBB2-targeted therapies. For instance, upregulation of ERBB3 or its ligands can bypass receptor blockade, reactivating PI3K/AKT and MAPK pathways. In colorectal cancer, the ErbB3-Akt feedback loop mediates cetuximab resistance, and targeting this loop with circSETD3 or miR-4667-5p mimics could restore sensitivity. Thus, co-targeting ERBB3 and its positive regulators may improve treatment outcomes.
From positive regulation of ERBB3 signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does ERBB3 kinase activity contribute to signaling? | Kinase-dead point mutation knock-in |
| What is the role of ERBB3 heterodimerization? | ERBB3 knockout with ERBB2 overexpression |
| How does UHRF2 regulate ErbB3/Ras/Raf? | UHRF2 knockout and overexpression in HCC cells |
| Does GATA3 control ERBB3 expression? | GATA3 knockout in breast cancer cell lines |
| Can circSETD3 modulate cetuximab resistance? | CircSETD3 overexpression and knockout in colorectal cancer cells |
| Is DUSP6 a therapeutic target in ovarian cancer? | DUSP6 knockout and inhibitor treatment |
How to Study the positive regulation of ERBB3 signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Loss-of-function effects on ERBB3 signaling | Identify positive regulators |
| CRISPR activation screen | Gain-of-function effects | Discover enhancers of ERBB3 expression |
| Phosphoproteomics | Phosphorylation changes | Map ERBB3 downstream signaling |
| RNA-seq | Transcriptional changes | Measure ERBB3 and target gene expression |
| Small RNA-seq | MicroRNA expression | Identify miRNAs regulating ERBB3 |
| Co-immunoprecipitation | Protein-protein interactions | Detect ERBB2-ERBB3 heterodimers |
| Cell viability assay | Proliferation and survival | Assess pathway dependency |
| Live-cell imaging | Receptor dynamics | Visualize ERBB3 trafficking |
CRISPR screening for pathway regulators
Genome-wide CRISPR knockout or activation screens can identify positive regulators of ERBB3 signaling. Cells expressing an ERBB3-dependent reporter or survival phenotype are transduced with a CRISPR library, and sgRNAs enriched under selective conditions are sequenced. This approach can uncover novel regulators such as UHRF2 or GATA3.
Phosphoproteomics and interactomics
Mass spectrometry-based phosphoproteomics can map ERBB3 phosphorylation sites and downstream signaling events upon ligand stimulation or genetic perturbation. Proximity labeling or co-immunoprecipitation coupled to mass spectrometry can identify proteins that positively regulate ERBB3 heterodimerization or stability.
Transcriptional and non-coding RNA profiling
RNA-seq and small RNA-seq can reveal changes in ERBB3 expression and microRNAs that regulate the pathway. For example, miR-17-5p and miR-20a-5p were identified as suppressors of ERBB3 signaling in HCC. Circular RNA profiling can uncover regulators like circSETD3 that sponge miRNAs.
Functional assays and imaging
Cell proliferation, migration, and survival assays are used to measure the functional impact of ERBB3 pathway modulation. Live-cell imaging of fluorescently tagged ERBB3 can visualize receptor internalization and heterodimerization dynamics. These methods complement genetic screens and omics approaches.
How CRISPR Can Be Used to Study GO:1905580 positive regulation of ERBB3 signaling pathway
Knockout
CRISPR knockout of ERBB3 or its positive regulators (e.g., ERBB2, UHRF2) can abolish pathway activity and reduce tumor cell proliferation. Knockout models are essential to establish causality and to identify synthetic lethal interactions. For example, ERBB3 knockout in breast cancer cells can reverse GATA3-mediated enrichment.
Point Mutation
Point mutations can be introduced to study specific residues. A kinase-dead mutation in ERBB2 or ERBB3 can dissect the requirement for kinase activity in heterodimer signaling. Mutations in downstream effectors like AKT1 (e.g., E17K) can mimic constitutive activation and reveal feedback mechanisms.
Knock-in
Knock-in of tagged ERBB3 (e.g., GFP or HA) allows for live-cell imaging and proteomic analysis of receptor complexes. Knock-in of patient-derived mutations in ERBB3 or its partners can model cancer-specific signaling. For instance, knock-in of mutant GATA3 can alter ERBB3 expression patterns.
Overexpression
Overexpression of ERBB3, NRG1, or UHRF2 can enhance pathway activity and drive oncogenic phenotypes. Overexpression models are useful for testing drug resistance and for validating positive regulators identified in screens. For example, circSETD3 overexpression can interrupt the ErbB3-Akt feedback loop and inhibit colorectal cancer progression.
How EDITGENE Supports positive regulation of ERBB3 signaling pathway Research
Researchers studying positive regulation of ERBB3 signaling pathway-related genes often need to determine whether a candidate gene is causally involved in pathway activation, and to dissect the precise molecular mechanisms. EDITGENE provides a comprehensive suite of CRISPR-based services to generate knockout, point mutation, knock-in, and overexpression cell models, as well as CRISPR library screening and bioinformatics support. These tools enable rigorous functional validation of genes identified from screens or omics studies.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of ERBB3 signaling pathway research.
Frequently Asked Questions About positive regulation of ERBB3 signaling pathway
What is GO:1905580?
GO:1905580 is the Gene Ontology term for positive regulation of ERBB3 signaling pathway, defined as any process that activates or increases the frequency, rate or extent of signaling through the ERBB3 receptor.
What genes are involved in positive regulation of ERBB3 signaling?
Key genes include ERBB3, ERBB2, NRG1, UHRF2, GATA2, GATA3, FOXA1, and microRNAs such as miR-17-5p and miR-20a-5p.
How is ERBB3 signaling activated?
ERBB3 is activated by ligand binding (e.g., neuregulin-1) followed by heterodimerization with ERBB2, which transphosphorylates ERBB3 and triggers downstream PI3K/AKT and MAPK pathways.
Why is ERBB3 important in cancer?
ERBB3 promotes cancer cell proliferation, survival, and resistance to targeted therapies, and its overexpression or hyperactivation is observed in breast, colorectal, hepatocellular, and ovarian cancers.
What is the role of ERBB2 in ERBB3 signaling?
ERBB2 is the preferred heterodimer partner for ERBB3; it provides kinase activity to phosphorylate ERBB3 and initiate downstream signaling.
How do microRNAs regulate ERBB3 signaling?
MicroRNAs such as miR-17-5p, miR-20a-5p, and miR-4667-5p can target ERBB3 or its feedback loops, thereby suppressing or modulating pathway activity.
What diseases are linked to ERBB3 signaling?
ERBB3 signaling is linked to various cancers (breast, colorectal, liver, ovarian) and to cardiotoxicity associated with ERBB2-targeted therapies.
How can CRISPR be used to study ERBB3 signaling?
CRISPR knockout, point mutation, knock-in, and overexpression models allow researchers to dissect the causal roles of ERBB3 and its regulators in pathway activation and disease.
What is the GATA2/GATA3-FOXA1 axis?
This transcriptional axis regulates subtype-specific ERBB3 enrichment in basal-like breast cancer, influencing pathway activity and tumor phenotype.
What is the HGF/ERBB3-NF-κB feedback loop?
It is a positive feedback loop in hepatocellular carcinoma where HGF signaling enhances ERBB3-NF-κB activity, promoting metastasis; miR-17-5p and miR-20a-5p can block this loop.
Conclusion
GO:1905580, positive regulation of ERBB3 signaling pathway, encompasses the diverse molecular events that enhance ERBB3 (HER3) signal transduction. From ligand-induced heterodimerization with ERBB2 to transcriptional and post-transcriptional control, these mechanisms are critical for normal physiology and are frequently dysregulated in cancer and cardiovascular disease. Understanding these positive regulators offers opportunities for therapeutic intervention, particularly in overcoming drug resistance. EDITGENE's CRISPR services provide the tools needed to functionally validate these regulators and accelerate discovery.
References
- 1. Wang Z. 2017. ErbB Receptors and Cancer.. Methods Mol Biol 1652:3-35 PMID: 28791631
- 2. Mikami Y et al.. 2026. Cardioprotective Role of Neuregulin1-ErbB2 Signaling Pathway: Its Physiological and Onco-Cardiological Roles in the Heart.. Biol Pharm Bull 49(1):24-29 PMID: 41485987
- 4. Li X et al.. 2025. CircSETD3 interrupts the bidirectional positive feedback of ErbB3 and Akt by sponging miR-4667-5p to inhibit colorectal cancer progression and cetuximab resistance.. Int J Biol Macromol 318(Pt 4):145352 PMID: 40541877
- 5. Sun J et al.. 2021. UHRF2 promotes Hepatocellular Carcinoma Progression by Upregulating ErbB3/Ras/Raf Signaling Pathway.. Int J Med Sci 18(14):3097-3105 PMID: 34400880
- 6. Tan C et al.. 2025. Subtype-specific HER3 enrichment in basal-like breast cancer is regulated via the GATA2/GATA3-FOXA1 axis.. Cancer Lett 633:218001 PMID: 40907734
- 7. Liu DL et al.. 2020. miR-17-5p and miR-20a-5p suppress postoperative metastasis of hepatocellular carcinoma via blocking HGF/ERBB3-NF-κB positive feedback loop.. Theranostics 10(8):3668-3683 PMID: 32206115
- 8. James NE et al.. 2019. Inhibition of DUSP6 sensitizes ovarian cancer cells to chemotherapeutic agents via regulation of ERK signaling response genes.. Oncotarget 10(36):3315-3327 PMID: 31164954
